Assessment of Cardiac Function, Microvascular Function and Cardiac Perfusion in Different Disease Stages of Hypertrophic Cardiomyopathy

Inclusion Criteria: One of below: * MYBPC3 mutation carrier * MYH7 mutation carrier * Genotype-negative first degree relative of a MYBPC3 or MYH7 mutation carrier All of the following criteria: * For the mutation carrier group: ≥18 years old * For the genotype-negative group: ≥30 years old MYBPC3 and MYH7 mutation carriers will be designated to one of three groups based on their maximum wall thickness, measured by echocardiography and MRI: * No phenotype: MWT \<12mm * Mild Phenotype: MWT ≥12 until \<15mm * HCM phenotype: MWT ≥15mm Exclusion Criteria: * ≥70 years old * Insulin-dependent diabetes mellitus * Pregnancy * Smoking * Claustrophobia * Pacemaker/ICD * Renal insufficiency \<30 GFR * Hypertension (systolic \>140mmHg or diastolic \>90mmHg) * For the genotype negative group, no phenotype group, and mild phenotype group: the use of blood pressure medication (diuretics, beta-blockers, ACE-inhibitors, angiotensin II receptor blockers, calcium channel blockers, alpha blockers) * For the HCM phenotype group: when it is unsafe to withhold from blood pressure medication (as specified above) for two days, as assessed by their own cardiologist * Left ventricular outflow tract gradient \> 50mmHg * Aortic valve disease * Left bundle branch block * (History of) Obstructive coronary artery disease * Chronic atrial fibrillation * Hormone replacement therapy * Second or third-degree AV-block, sick-sinussyndrome, prolonged QT-interval * Asthma and other obstructive pulmonary diseases * Previous adverse reaction to adenosine or dotarem